On March 3, 2025, the FDA approved Celltrion’s denosumab biosimilars, STOBOCLO® (denosumab-bmwo; 60 mg/mL injection) and OSENVELT® (denosumab-bmwo; ...
On March 5, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West Virginia’s entry ...
Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt ...
Korea JoongAng Daily on MSN4d
Celltrion's bone disease biosimilars get approval in U.S.Celltrion, a major Korean biopharmaceutical firm, said Tuesday that its two new biosimilars for bone disease treatment, Stoboclo and Osenvelt, have obtained approval from the United States.
Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a ...
Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) ...
The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...
South Korea-based Celltrion today announced that the US Food and Drug Administration (FDA) has approved Stoboclo and Osenvelt ...
GlobalData on MSN11d
EC authorises Celltrion’s Avtozma for multiple indicationsCelltrion has secured marketing authorisation from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Chugai ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback